An integrative genomic and proteomic analysis of PIK3CA, PTEN and AKT mutations in breast cancer

Journal Article · Tue May 06 04:00:00 EDT 2008 · Cancer Research

DOI:https://doi.org/10.1158/0008-5472.CAN-07-6854· OSTI ID:952574

Stemke-Hale, Katherine; Gonzalez-Angulo, Ana Maria; Lluch, Ana; Neve, Richard M; Kuo, Wen-Lin; Davies, Michael; Carey, Mark; Hu, Zhi; Guan, Yinghui; Sahin, Aysegul; Symmans, W Fraser; Pusztai, Lajos; Nolden, Laura K; Horlings, Hugo; Berns, Katrien; Hung, Mien-Chie; van de Vijver, Marc J; Valero, Vicente; Gray, Joe W; Bernards, Rene ; Mills, Gordon B; Hennessy, Bryan T

Phosphatidylinositol-3-kinase (PI3K)/AKT pathway aberrations are common in cancer. By applying mass spectroscopy-based sequencing and reverse phase protein arrays to 547 human breast cancers and 41 cell lines, we determined the subtype specificity and signaling effects of PIK3CA, AKT and PTEN mutations, and the effects of PIK3CA mutations on responsiveness to PI3K inhibition in-vitro and on outcome after adjuvant tamoxifen. PIK3CA mutations were more common in hormone receptor positive (33.8%) and HER2-positive (24.6%) than in basal-like tumors (8.3%). AKT1 (1.4%) and PTEN (2.3%) mutations were restricted to hormone receptor-positive cancers with PTEN protein levels also being significantly lower in hormone receptor-positive cancers. Unlike AKT1 mutations, PIK3CA (39%) and PTEN (20%) mutations were more common in cell lines than tumors, suggesting a selection for these but not AKT1 mutations during adaptation to culture. PIK3CA mutations did not have a significant impact on outcome in 166 hormone receptor-positive breast cancer patients after adjuvant tamoxifen. PIK3CA mutations, in comparison with PTEN loss and AKT1 mutations, were associated with significantly less and indeed inconsistent activation of AKT and of downstream PI3K/AKT signaling in tumors and cell lines, and PTEN loss and PIK3CA mutation were frequently concordant, suggesting different contributions to pathophysiology. PTEN loss but not PIK3CA mutations rendered cells sensitive to growth inhibition by the PI3K inhibitor LY294002. Thus, PI3K pathway aberrations likely play a distinct role in the pathogenesis of different breast cancer subtypes. The specific aberration may have implications for the selection of PI3K-targeted therapies in hormone receptor-positive breast cancer.

• Research Organization: Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA (US)
• Sponsoring Organization: Life Sciences Division
• DOE Contract Number: AC02-05CH11231
• OSTI ID: 952574
• Report Number(s): LBNL-479E
• Journal Information: Cancer Research, Journal Name: Cancer Research Journal Issue: 15 Vol. 68; ISSN 0008-5472; ISSN CNREA8
• Country of Publication: United States
• Language: English

Related Subjects

59 BASIC BIOLOGICAL SCIENCES
GROWTH
HORMONES
IN VITRO
INHIBITION
MAMMARY GLANDS
MUTATIONS
NEOPLASMS
PATHOGENESIS
PATIENTS
PROTEINS
SPECIFICITY
TAMOXIFEN